Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.
View Top Employees from Inhibikase Therapeutics, Inc.| Website | http://inhibikase.com |
| Ticker | IKT |
| Revenue | $1 million |
| Employees | 11 (6 on RocketReach) |
| Address | 3350 RIVERWOOD PARKWAY, Atlanta, Georgia 30303, US |
| Phone | (678) 392-3419 |
| Technologies |
JavaScript,
HTML,
Twitter
+15 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Health Care, Pharmaceuticals, Health Diagnostics, Healthcare, Therapeutics |
| Competitors | Can Fite BioPharma (CANFY), DelMar Pharmaceuticals, Evgen Pharma, Moleculin Biotech, Inc., Sun BioPharma |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Inhibikase Therapeutics, Inc. employee's phone or email?
Inhibikase Therapeutics, Inc. Questions
The Inhibikase Therapeutics, Inc. annual revenue was $1 million in 2024.
Chris Meyer is the Vice President of Clinical Operations of Inhibikase Therapeutics, Inc..
6 people are employed at Inhibikase Therapeutics, Inc..
Inhibikase Therapeutics, Inc. is based in Atlanta, Georgia.
The NAICS codes for Inhibikase Therapeutics, Inc. are [3254, 32541, 325, 32].
The SIC codes for Inhibikase Therapeutics, Inc. are [283, 28].
Top Inhibikase Therapeutics, Inc. Employees
Related Companies
